« Return to News | Technology Solutions

Genstar Capital to acquire ERT

Tuesday, April 10, 2012 11:24 AM

Philadelphia-based eResearch Technology, a technology-driven provider of health outcomes research services to sponsors and CROs, has agreed to be acquired by affiliates of Genstar Capital, a middle market private equity firm, for $8 per share in cash in a transaction valued at approximately $400 million.

The proposed transaction has been approved unanimously by the ERT board of directors. The $8 per share represents a premium of approximately 38% over ERT's average closing share price for the 90 trading days ending April 9, 2012, and 42% over the 52-week average.

"We are pleased to announce this transaction with Genstar, whose experienced team of healthcare executives can provide strategic oversight, as well as acquisition capital,  to expand the company's service offering and market opportunities,” said Dr. Jeffrey Litwin, CEO of ERT. “They will help position ERT to better serve our clinical research clients by continuing to fund the innovative devices and services that have made us the premier provider of health outcomes research services."

Robert Weltman, managing director of Genstar, said, "ERT is an attractive opportunity that fits with Genstar's outsourcing thesis within the life sciences and pharmaceutical services sector. We are excited about helping the company evolve its offering and better serve its customers."

Pending stockholder approval and satisfaction of normal regulatory and closing conditions, the transaction is expected to be completed during the third quarter, after which ERT will become a privately held company and its stock will no longer trade on Nasdaq.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.